Biocompatibility and degradation studies of poly(L-lactide-co-trimethylene carbonate) copolymers as cardiac occluders

Laishun Xi,¹ Yuandou Wang,² Feng Su,^{1,2*} Qingzhen Zhu,¹ Suming Li^{3*}

¹ State Key Laboratory Base of Eco-chemical Engineering, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China

² Institute of High Performance Polymers, Qingdao University of Science and Technology, Qingdao 266042, China

³ Institut Européen des Membranes, UMR CNRS 5635, Université de Montpellier, 34095 Montpellier, France

Correspondence to: F. Su (E-mail: sufeng@qust.edu.cn) and S. Li (E-mail: suming.li@umontpellier.fr)

Abstract

Poly(L-lactide-co-trimethylene carbonate) (PLT) copolymers were synthesized by ring opening polymerization of L-lactide (LLA) and trimethylene carbonate (TMC). The resulting copolymers were characterized by using ¹H NMR, GPC, DSC and tensile tests. The copolymer properties are dependent on the TMC content. In vitro degradation of copolymers was carried out in pH 7.4 phosphate buffered saline at 37 °C. The results show that copolymers with higher TMC content are more resistant to degradation. The cytotoxicity and hemocompatibility of copolymers were evaluated from MTT assay, hemolysis test, dynamic clotting time and plasma recalcification time. Results indicate that the copolymers present very low cytotoxicity and good hemocompatibility.

Cardiac occluders were designed and fabricated using 3D printing. In vivo degradation of occluders was realized by intramuscular implantation in the back of rabbits. The occluders were almost totally degraded in 120 days. Visual observation and H&E staining analysis confirmed the good tissue compatibility of occluders. All these findings suggest that PLLA-TMC copolymers could be promising for potential applications as degradable occluder

material.

Keywords: copolymer; 3D printing; biocompatibility; cardiac occluder; in vitro degradation; in vivo implantation

1. Introduction

In the past decades, great progress has been made in the treatment of congenital heart diseases by the use of cardiac occluders. [1-6] Amplatzer occluders are the most widely used occluders in clinical applications. They are double-disc devices made from Nitinol wires tightly woven into two flat discs with a connecting waist. Soft polymeric meshes are placed inside the discs to block the blood stream. These occluders present good short-term curative effect, but the permanent presence of metallic devices in the heart often leads to various adverse reactions such as hemolysis, thrombosis, perforation, allergic skin and dermis, and even neurological complications. [7] Therefore, occluders based on degradable materials have received more and more attention.

BioSTAR occluders use an acellular porcine intestinal collagen layer to replace non degradable meshes. Heparin is coated on the device to reduce protein or blood cell deposition and thrombus formation. But the device cannot be completely resorbed as the framework is made of traditional metals or alloys. [8] Totally degradable occluders have been developed in the past years. Duong et al. developed PFO occluders composed of two self-expanding umbrellas linked by a stem, and 4 spokes to hold the mesh. The device consists of degradable poly(ϵ -caprolactone) (PCL) and poly(lactide-co- ϵ -caprolactone) (PLC). [9] Zhu et al. [10] reported Improved Amplatzer occluders made of braided filaments of poly(para-dioxanone) (PDO) and poly(L-lactide) (PLLA) nonwoven fabric as a barrier film. Recently, implantation of totally degradable occluders made of PDO and PLLA was successfully performed in a clinic operation.

PLLA is a degradable polyester widely used in various biomedical applications such as drug carriers, surgical implants and sutures because of its biocompatibility and mechanical strength. [11] PLLA exhibits good tensile strength up to 60 MPa. [12] But PLLA is brittle and highly crystalline, and acidic degradation products can lead to inflammatory reaction. [13,14] Furthermore, non-integrative devices with different degradation times could lead to defect recanalization or abscission of components. Hence, it is of major importance to develop degradable occluders with sufficient strength, good elasticity and integrative design.

The toughness of PLLA based copolymers can be improved by copolymerization of L-lactide (L-LA) with other monomers, such as 1,3-trimethylene carbonate (TMC), glycolide (GA), and ϵ -caprolactone (ϵ -CL). [15,16] Poly(1,3-trimethylene carbonate) (PTMC) is an elastomer with a T_g of -15°C . [17] PTMC degrades extremely slowly by pure hydrolysis, yielding neutral degradation products, i.e., diols and carbon dioxide. In contrast, PTMC rapidly degrades *in vivo* by enzyme catalyzed surface erosion. [18] PTMC is largely used as a softening component of copolymers for applications as suture material, soft tissue engineering scaffold, and drug carrier due to its flexibility and biocompatibility. [19-21]

PLLA-TMC (PLT) copolymers have been investigated for applications as heart constructs and nerve regeneration guides, [22,23] cartilage implants, [24] and sustained drug release carrier [25, 26] In our previous work, copolymers of L-lactide or DL-lactide and TMC with various compositions and chain microstructures were synthesized. The thermal properties, degradation behaviors as well as mechanical properties of the copolymers were studied to evaluate their potential as cardiovascular stent material. [27-29] The results showed that PLT copolymers with high LLA contents exhibit high tensile strength and high crystallinity, but slow degradation rate.

In this paper, PLT copolymers with LLA/TMC molar ratios from 75/25 to 60/40 were synthesized and characterized. The *in vitro* degradation and biocompatibility of the

copolymers were investigated to evaluate their potential as degradable occluder material. Occluders of the copolymers were fabricated by 3D printing. The histocompatibility and *in vivo* degradation of the printed occluders were investigated. The results are reported herein in comparison with literature.

2 Materials and Methods

2.1 Materials

1,3-propanediol and L-lactic acid were purchased from Tianjin Kemiou Chemical Reagent Co., Ltd (China). Dibutyltin dilaurate, diethyl carbonate, antimony trioxide, zinc powder, sodium metal and stannous octoate ($\text{Sn}(\text{Oct})_2$) were obtained from Sinopharm Chemical Reagent Co., Ltd (China). The used organic solvents were all of analytic grade.

2.2 Synthesis

LLA and TMC monomers were synthesized as previously reported in literature. [30] The crude products were purified by recrystallization in ethyl acetate or mixture of diethyl ether and acetone (V: V = 4: 1). PLT copolymers were synthesized by ring-opening polymerization of LLA and TMC using stannous octoate as catalyst. [31] Taking PLT 75/25 as example, LLA (32.36 g), TMC (7.64 g) and the catalyst (0.061 g) were added into a round-bottomed flask, and degassed. The overall comonomers/catalyst ratio was 2000/1. The polymerization was carried out under vacuum at 130°C for 72 h. The product was dissolved in dichloromethane, and precipitated in ethanol. Finally the product was thoroughly dried under vacuum at 50°C for 72 h.

2.3 Film and occluder fabrication

Copolymer films were prepared by solution casting method. [30] The copolymers were dissolved in dichloromethane at 10.0 w/v %, and the resulting solutions were poured onto a

glass plate. The solvent was evaporated overnight, followed by vacuum drying for 72 h. The films were then cut into rectangular samples of 10×75×0.2 mm or square samples of 10×10×0.2 mm for tensile tests and in vitro degradation studies, respectively.

A 3D occluder model with dumbbell shape and hollow structure was designed using CAD software with parameters of the clinically used devices as reference, and processed using a 3D printer (UN-biomedical 3d printer, Anyprint, China). The printer parameters were set as follows: print temperature 140°C, nozzle diameter 0.3 mm, discharge speed 0.012 g/s, printing rate 4 mm/s, and printing layer thickness 0.2 mm.

2.4 Characterization

Proton nuclear magnetic resonance (¹H NMR). ¹H NMR was performed on Bruker AVANCE III 500 spectrometer operating at 500 MHz, using deuterated chloroform (CDCl₃) as a solvent. Chemical shifts (δ) were given in ppm using tetramethylsilane (TMS) as an internal reference.

Gel permeation chromatography (GPC). GPC was conducted on a Shimadzu apparatus (Waters 410) equipped with a refractometer, using tetrahydrofuran (THF) as mobile phase at a flow rate of 1.0 mL/min. 60 μL of 1.0 mg/mL sample solution were injected for measurement, and polystyrene standards were used for calibration.

Differential scanning calorimetry (DSC). DSC was performed using a DSC10 instrument (TA Instruments). 5.0 mg of samples were used for each analysis. A first heating scan was realized from 0°C to 200°C at 10°C/min, followed by fast cooling down to 0°C at 50°C/min, and a second heating scan to 200°C at 10°C/min.

Tensile testing. Tensile tests were carried out on a GT-TCS-2000 Universal tensile machine at 25°C, using rectangular samples of 10×75×0.2 mm. The inductor load capacity was 500 N, and the tensile rate was 50 mm/min. All results are the average of triplicate measurements.

2.5 In vitro degradation

Square samples with dimensions of 10×10×0.2 mm were weighed and placed in vials containing 0.1 M pH = 7.4 phosphate buffered saline (PBS) at 37°C. 0.01% (w/v) sodium azide was added to inhibit the growth of bacteria. At predetermined time intervals, samples were withdrawn from the vials and washed with distilled water. After wiping, the samples were vacuum dried up to constant weight before analyses.

2.6 Hemocompatibility

50 mg of films were immersed in 10 mL 0.9% saline, and stirred 72 hours to obtain extract for hemocompatibility test.

Hemolysis. Hemolysis testing was performed according to the ISO 10993-4-2002 standard, using fresh ACD anticoagulated rabbit whole blood composed of 90% of blood and 10% of 3.8% sodium citrate. Distilled water was taken as positive control, and 0.9% saline as negative control. [32,33] 10 mL of sample extract in a test tube were thermostated at 37°C for 30 min. Then 0.2 mL of diluted blood with blood/saline volume ratio of 4/5 were added into the tubes, and maintained at 37°C for 1 h. After incubation, the samples were centrifuged at 3000 r/min for 5 min. The optical density (OD) of the supernatants was measured at an absorbance wavelength of 545 nm by using UV spectrophotometer (GBC Cintra 10e, Australia). The hemolytic ratio (HR) was calculated from the OD data of the test sample and controls using the following formula [34]:

$$HR (\%) = [(OD_{\text{test}} - OD_{\text{negative}}) / (OD_{\text{positive}} - OD_{\text{negative}})] \times 100 \quad (1)$$

Measurements were made in triplicate (n = 3).

Dynamic clotting time. A method similar to the work described by Zhang et al. [35] was used for dynamic clotting time measurement. In a test tube were added 10 µL of the sample extract and 10 µL of 0.2 M CaCl₂ solution. After 5 min incubation at 37°C, 80 µL of ACD blood were introduced in the tube. At different time intervals up to 120 min, 20 mL of

distilled water were carefully added along the tube wall, and the supernatant was collected. The OD value of the supernatant was determined at 490 nm with a microplate reader (Elx800, BioTek, USA). Saline was taken as the negative control, and 0.2 M CaCl_2 solution as the positive control. The relative clotting time of samples is obtained from the curves of OD *versus* time changes. The experiments were repeated five times for each sample ($n = 5$).

Plasma recalcification time (PRT). The PRT was determined by using Nie's method. [36] Fresh ACD anticoagulated rabbit whole blood was added into an ACD tube, and centrifuged at 3000 r/min for 10 min to collect platelet poor plasma (PPP). 0.1 mL sample extract was added to a test tube, followed by addition of 0.1 mL PPP. After 2 min incubation in a water bath at 37°C, 0.1 mL of 0.025 M CaCl_2 solution was added. Every 1 or 2 s the test tube was tilted so as to observe the state of PPP. The clotting time was taken when the plasma solution no longer flowed in the inclined tube. Silicified and unsilicified glass tubes were taken as negative and positive controls, respectively. Triplicate measurements were made for each copolymer sample ($n = 3$).

2.7 Cytotoxicity

Both sides of copolymer films (30 mg) were exposed to UV for sterilization at room temperature for 12 h, and then soaked in 5 mL Dulbecco's Modified Eagle Medium (DMEM). The samples were placed in water bath oscillator at 37°C for 72 h in a sterile environment, followed by centrifugation at 1200 rpm for 5 min. Finally the supernatant was collected for MTT experiment.

MTT test is commonly used to evaluate the cytotoxicity of biomaterials *in vitro*. [34] L-929 cells (mouse fibroblasts) in the logarithmic growth phase were collected, and diluted with DMEM containing 10% fetal bovine serum to a cell concentration of 1×10^4 cells/mL. 100 μL cell suspension was added in a well of 96-well plate, and placed in 5% CO_2 incubator at 37°C. After 24 h incubation, the culture medium was removed and twice washed with PBS.

100 μ L sample extract was then added. After incubation for 24, 48 and 72 h, the supernatant of each well was removed and replaced with 20 μ L MTT solution at 5 mg/mL and 80 μ L DMEM. The liquid in the well was removed after 4 h incubation. 150 μ L DMSO was then added, and shaken 10 min. Finally, the OD value was measured at 490 nm by using microplate reader (Elx800, BioTek, USA). DMEM containing 10% fetal bovine serum was taken as the negative control, and 6.4% phenol solution as the positive control. Triplicate measurements were made for all samples. The relative growth rate (RGR) was calculated according to the following formula [37]:

$$\text{RGR (\%)} = (\text{OD}_{\text{test sample}} / \text{OD}_{\text{negative control}}) \times 100 \quad (2)$$

The cytotoxicity is generally noted in 0-5 levels according to the RGR value. Level 0, 1, 2, 3, 4 and 5 corresponds to $\text{RGR} \geq 100\%$, $100\% > \text{RGR} \geq 75\%$, $75\% > \text{RGR} \geq 50\%$, $50\% > \text{RGR} \geq 25\%$, $25\% > \text{RGR} \geq 1\%$ and $\text{RGR} > 1\%$, respectively.

2.8 Histocompatibility and in vivo degradation

PLT copolymer was processed into occluder samples by 3D printing. The thus obtained samples were soaked in 70% ethanol for 24 h, and then twice washed by using aseptic PBS. 15 New Zealand white rabbits were anesthetized by injection of 1 mL/kg of pentobarbital sodium into the auricular vein. 4 occluders were implanted into the muscle on the back with a distance of no less than 5 cm between them. The post-operation rabbits were placed in a feeding environment at a temperature of 20 ~ 25°C and humidity of 40% ~ 60%. At preset time intervals (10, 30, 60, 90 and 120 days), three randomly selected rabbits were sacrificed. The occluders were explanted, and the surrounding tissues removed. The tissues were fixed with 10% formaldehyde solution for 48 h. After rinsing with water, the tissues were dehydrated with a series of ethyl alcohol solutions of 70%, 80%, 90%, 95% and 100%. Then the tissues were made into the paraffin embedding section of a thickness of 5 cm for hematoxylin and eosin (H&E) staining analysis. The inflammatory reaction and fibrocystic

cavity formation were observed under the microscope.

The recovered occluder samples were successively immersed in type II collagenase solution (2.5 g/L), and trypase solution (2.0 g/L) for 1 h. The samples were then rinsed twice with deionized water, and vacuum dried for 1 week up to constant weight. Finally the degraded samples were characterized by using ^1H NMR, GPC and DSC.

3 Result and Discussions

3.1 Characterization of copolymers

A series of PLT copolymers with LLA/TMC molar ratios of 75/25, 70/30, 65/35, and 60/40 were synthesized by ring-opening polymerization, using stannous octoate as initiator. The chemical composition of the copolymers was determined from ^1H -NMR spectra as shown in Figure 1. The signal at 5.20 ppm belongs to the CH protons of main chain LLA units, and the smaller signal at 5.05 ppm is assigned to the CH protons of LLA linking to TMC units. [38] The signals of the CH_3 protons of LLA are observed in the 1.5-1.60 ppm (b) range. On the other hand, the signals of the methylene groups of TMC units are detected at 2.03 ppm (d) and 4.24 ppm (c), respectively. The LLA/TMC molar ratio of the copolymers was determined from the integration areas of LLA signal at 5.20 ppm and TMC signal at 4.24 ppm. As shown in Table 1, the composition of the copolymers is close to the feed ratio, which well corroborates with high conversion of monomers. The average lengths of lactidyl and carbonate blocks (l_{LL} and l_{TMC} , respectively) in PLT polymers were determined from ^{13}C NMR as reported in literature. [27] Both l_{LL} and l_{TMC} increase with increase of the corresponding component's content. The l_{LL} increases from 5.29 for PLT 65/35 to 7.55 for PLT 75/25, whereas l_{TMC} decreases from 2.70 to 2.57 in the meantime.

GPC was employed to measure the molar masses and dispersity of PLT copolymers as shown in Table 1. The M_n varies from 86100 for PLT 60/40 to 113800 for PLT 75/25, and the

dispersity ($\bar{D} = M_w/M_n$) varies from 2.0 to 1.8, in agreement with rather narrow molar mass distribution.

Figure 1. ^1H NMR spectrum of PLT 70/30 copolymer in CDCl_3 .

Table 1. Characteristics of PLLA/TMC (PLT) copolymers.

Copolymer	LLA/TMC ^a	l_{LLA} ^b	l_{TMC} ^b	M_n ^c	$\bar{D}$ ^c	T_g ($^{\circ}\text{C}$) ^d	σ (MPa) ^e	E (%) ^e
PLT 75/25	74.6/25.4	7.55	2.57	113800	1.8	42.8	31.5	87.0
PLT 70/30	70.2/29.8	6.42	2.64	108100	1.8	40.8	20.2	269.1
PLT 65/35	66.2/33.8	5.29	2.70	96500	1.9	37.2	18.3	386.1
PLT 60/40	59.4/40.6	- ^f	- ^f	86100	2.0	34.1	16.5	512.0

^a Determined by ^1H NMR.

^b Determined by ^{13}C NMR.

^c Determined by GPC.

^d Determined by DSC.

^e Determined by tensile tests.

^f Not determined.

The glass transition temperature (T_g) of the copolymers was obtained from DSC (Table 1). All copolymers exhibit only one glass transition temperature, suggesting that the copolymer has a relatively random chain structure. Comparison of the T_g data shows that the addition of TMC component leads to T_g decrease from 42.8°C for PLT 75/25 to 34.1°C for PLT 60/40. This could be assigned to fact that PTMC has lower T_g and higher chain flexibility

as compared to PLLA. [39,40] All the copolymers are amorphous as no melting peak was detected. According to the literature, [41] PLLA/TMC copolymers can crystallize when the content of TMC is below 15 mol%. It has been reported that biomaterials with high crystallinity could lead to late complications such as inflammatory reactions. [18] Thus the amorphousness of PLT copolymers should be beneficial for uses as degradable occluders.

The mechanical properties are of crucial importance for occluder materials. Dong et al. [42] developed PLLA-based terpolymers for applications as biodegradable vascular stent material. Vascular stents should exhibit higher mechanical strength to prevent recoil due to vessel pressure as compared to occluders, and need to support the vessels for about 6 months. In the case of occluders, mechanical support is required for 1-3 months.

The tensile strength (σ) and elongation at break (ϵ) of PLT copolymers are shown in Table 1. It appears that the composition strongly affect the mechanical properties of copolymers. PLLA homopolymer has a tensile strength of 55.6 MPa and an elongation at break of 9%. [41] With introduction of the TMC comonomer, the tensile strength of PLT copolymers decreases from 31.5 MPa for PLT 75/25 to 16.5 MPa for PLT 60/40, the elongation at break increases from 87 % to 512 %. The higher the TMC content, the lower the tensile strength, and the higher the elongation at break. Therefore, introduction of flexible TMC component into rigid PLLA chains leads to decrease of the tensile strength and increase of the elongation at break of copolymers.

3.2 In vitro degradation

PLT 75/25, PLT 70/30 and PLT 65/65 were selected for in vitro degradation studies. PLT 60/40 was not considered as its T_g (34.1°C) is below the body temperature.

Mass loss and water uptake. Mass loss refers to the ratio of soluble species produced during degradation which are dissolved in the medium, and water uptake reflects the content

of absorbed water in the remaining polymers. Water absorption and mass loss were obtained according to the following equations [32]:

$$\text{Mass loss (\%)} = 100(W_i - W_d)/W_i \quad (3)$$

$$\text{Water uptake (\%)} = 100(W_w - W_d)/W_d \quad (4)$$

where W_i represents the initial weight, W_d the dry weight after vacuum drying, and W_w the wet weight of samples after degradation.

Figure 2 presents water uptake and mass loss changes of PLT copolymers during degradation. During the degradation period up to 90 days, 6.5%, 4.9%, and 4.7% of mass loss are obtained for PLT 75/25, PLT 70/30, and PLT 65/35, respectively. Larger difference was observed in water uptake profiles. Water uptake attained nearly 15% for PLT 75/25 after 90 days, whereas PLT 70/30 and PLT 65/35 had a water uptake of 11% and 9%, respectively. These findings could be attributed to the fact that PTMC is more resistant to hydrolytic degradation, in agreement with the work reported by Zhang et al. [43] The authors observed that long TMC sequences can be hardly hydrolyzed although PLT copolymers with TMC content above 20 mol% are amorphous materials.

Figure 2. Mass loss (A) and water uptake changes (B) of PLT 75/25, PLT 70/30 and PLT 65/35 during degradation.

Molar mass changes during degradation. The variation of M_n during degradation is shown in Figure 3. A molar mass decrease is observed for all samples from the very beginning.

Actually, water penetrates the PLT samples once immersed in the PBS medium. The chains are cleaved by hydrolysis of ester and carbonate bonds, resulting in the decrease of molar mass. The degradation rate of PLT 65/35 is the slowest, with M_n continuously decreasing from 96500 to 56900 at 90 days, equivalent to 59% of the initial value. PLT 70/30 degrades slightly faster than PLT 65/35. The M_n decreases from 108100 to 61610 at 90 days, equivalent to 57% of the initial value. PLT 75/25 shows the fastest decrease of M_n among all the copolymers with 52% remaining molar mass during the degradation period.

It is worthwhile to point out that polymeric materials lose their mechanical strength when the M_n is below 25000. [18] The ideal mechanical support time for heart occluders is 2-3 months. Therefore, the three copolymers seem to meet the requirement from the viewpoint of mechanical support during degradation.

Figure 3. Molar mass decrease ratio of PLT 75/25, PLT 70/30 and PLT 65/35 during degradation.

Compositional changes during degradation. The compositional changes of copolymers during degradation were determined by ^1H NMR as shown in Table 2. The LLA/TMC ratio of PLT 75/25, PLT 70/30, PLT 65/35 decreases from 3.13 to 2.86, from 2.38 to 2.23, and from 1.94 to 1.82 during 90 days degradation, respectively. In other words, LLA

units are preferentially degraded because they are more degradable than TMC units, as previously reported in literature. [27,44]

Table 2. LLA/TMC ratio changes of PLT copolymers during *in vitro* degradation.

Time (days)	LLA/TMC ratio		
	PLT 75/25	PLT 70/30	PLT 65/35
0	3.13	2.38	1.94
40	3.08	2.33	1.85
60	2.94	2.30	1.84
90	2.86	2.23	1.82

3.3 Hemocompatibility evaluation

Hemocompatibility is a key property of biomaterials which are used in contact with blood. Hemolytic ratio, dynamic clotting time and plasma recalcification time were measured to evaluate the hemocompatibility of copolymers.

Hemolysis. Hemolysis test is commonly used for the screening of medical materials. It is generally admitted that a material would not cause hemolysis and can be used for medical applications if the hemolysis ratio is below 5%, and *vice versa*. Table 3 presents the hemolysis ratio of the PLT copolymers. The positive control had an absorbance value of 0.707, whereas the OD value of the negative control group was 0.0033. These values are within the recommended range of ISO 10993-4. The hemolysis ratio of all samples is well below 5%, indicating that the copolymers have little effect on the erythrocytes, and are thus safe for medical applications.

Table 3. Hemolysis data of the PLT copolymers.

Copolymer	OD value	Hemolysis ratio (%)
PLT 75/25	0.0063±0.0014	0.426±0.085
PLT 70/30	0.0057±0.0006	0.340±0.020
PLT 65/35	0.0084±0.0006	0.582±0.164
PLT 60/40	0.0067±0.0015	0.475±0.105
Negative control	0.0033±0.0006	-

Positive control	0.7070 ± 0.0360	-
------------------	---------------------	---

Dynamic clotting time. The clotting time allows to evaluate the activation degree of intrinsic coagulation factors, and is thus used to assess the influence of biomaterials on the coagulation process. Absorbance-time curves reflect the coagulation trend of the various samples as shown in Figure 4. The time at which the absorbance equals to 0.1 is generally taken as the clotting time. [45] The initial coagulation time of PLT 75/25, PLT 70/30, PLT 65/35, PLT 60/40 is estimated to be 28, 33, 35, 36 min, respectively, which is shorter than that of the negative control (48 min), but much longer than that of the positive control (6 min). These findings suggest that the copolymers have little effect on the erythrocytes.

Figure 4. Absorbance-time curves of copolymers in comparison with the controls.

Plasma recalcification time. Plasma recalcification profile allows to measure the time of clot formation in recalcified blood, and can serve as indicator of the intrinsic coagulation system. The plasma recalcification time (PRT) of materials is considered to be significant if it is above 140% that of the positive control (not silicified glass). [46,47] As shown in Figure 5, the PRT of PLT 75/25, PLT 70/30, PLT 65/35, PLT 60/40 is 279.7 ± 5.4 , 322.0 ± 6.9 , 342.3 ± 7.3 and 335.8 ± 9.6 s, respectively. The PRT of copolymers is shorter than that of the negative

control (372.6 ± 10.8 s), but much longer than that of the positive control (154.3 ± 9.1 s). Moreover, the PRT of all copolymers is largely above 140% that of the positive control, thus indicating that they do not have noticeable effect on the intrinsic coagulation pathway.

Figure 5. Plasma recalcification time of PLT 75/25, PLT 70/30, PLT 65/35 and PLT 60/40 copolymers. ** indicates $p < 0.01$, *** $p < 0.001$, and * $p > 0.05$.

3.4 Cytotoxicity evaluation

L-929 cells (mouse fibroblasts) are a commonly used standard cell line for cytotoxicity evaluation of biomaterials which are to be used as medical implants and thus in direct contact with fibroblasts. The cytotoxicity of PLT copolymers was evaluated by using MTT method. [48] Figure 6 shows the viability of cells after co-culture with copolymer extracts for 1, 2 and 3 days. The L-929 cells' viability varies with the incubation time, and the number of L-929 cells reaches a maximum at the second day. The RGR value is above 100% for all copolymer samples, corresponding to a cytotoxicity level of 0 (Table 4). On the other hand, the survival ratio of the cells in the positive control is very low, and the cytotoxicity level is 4. These findings show that there was no release of cytotoxic species in the copolymer extracts.

Figure 6. Effect of PLT copolymers on L-929 cells growth in comparison with controls.

Table 4. RGR values and cytotoxicity levels of PLT copolymers during 3 days' incubation with L-929 cells.

Copolymer	1d		2d		3d	
	RGR (%)	Level	RGR (%)	Level	RGR (%)	Level
PLT 75/25	115.0±8.7	0	101.7±7.2	0	128.9±12.4	0
PLT 70/30	118.9±5.8	0	101.9±6.3	0	118.8±8.4	0
PLT 65/35	122.7±10.8	0	107.1±5.0	0	126.9±6.8	0
PLT 60/40	117.7±4.7	0	111.2±6.2	0	121.1±11.2	0
Negative Control	100	0	100	0	100	0
Positive Control	8.3±2.7	4	4.8±1.5	4	9.1±1.8	4

3.5 In vivo degradation

PLT 70/30 copolymer was selected for the fabrication of occluder samples by 3D printing due to its outstanding overall properties. A hollow structure with dumbbell shape was designed as shown in Figure 7A. The diameter and the total height are both 12 mm. The thickness of the wall is 0.2 mm. The 3D printed occluder is shown in Figure 7B. The occluder samples were implanted into New Zealand white rabbit muscle tissue, and removed at 10, 30, 60, 90, and 120 days, respectively. No death occurred during the operation. No abnormality, redness or infection was observed in the post-operation period.

Figure 7. Design (A) and 3D printed occluder sample (B) of PLT 70/30.

Figure 8. Shape changes during in vivo degradation of the occluders: (A) 10 days; (B) 30 days; (C) 60 days; (D) 90 days.

The occluder appeared flattened after 10 days' implantation as shown in Figure 8A. This phenomenon could be attributed to the fact that the T_g of the copolymer is only slightly slightly above the body temperature. Thus the copolymer chains have a certain mobility. And with the muscle pressure and movement, the hollow occluder structure collapsed. At 30 days, the occluder became more deformed (Figure 8B). And at 60 and 90 days, the occluder appeared much smaller (Figure 8C, D). Finally at 120 days, the occluder was almost completely degraded, leaving dispersed debris around the muscle tissue.

Table 5 presents the changes of LLA/TMC ratio, M_n and dispersity of occluder samples during *in vivo* degradation. The M_n of occluder sample was initially 55970, which was much lower than the value of 108100 of the copolymer. In fact, the 3D printing at high temperature led to a strong M_n decrease, in agreement with thermal degradation of the copolymer. Therefore, 3D printing conditions should be strictly controlled to minimize thermal degradation. Especially, the copolymer should be thoroughly dried prior to processing. A constant decrease of M_n is observed during degradation from initial 55970 to 1290 at 90 days. The dispersity of molar masses remained almost unchanged. On the other hand, the LLA/TMC ratio decreased continuously from 2.38 initially to 1.92 at 60 days. These findings are consistent with *in vitro* degradation data, and confirmed faster degradation of LLA units than TMC ones in amorphous zones. Surprisingly, a sharp increase of LLA/TMC ratio up to 4.26 was observed at the last stage of degradation, which could be assigned to crystallization of PLLA segments as shown in Figure 9.

Table 5. Composition and molar mass changes of PLT 70/30 copolymer during *in vivo* degradation.

Time (days)	LLA/TMC ratio ^a	M_n ^b	$\bar{D}$ ^b
0	2.38	55970	1.8
10	2.22	30000	1.7
30	2.07	15500	1.5
60	1.92	10000	1.8
90	4.26	1290	1.9

^a Determined by ¹H NMR.

^b Determined by GPC.

Figure 9. DSC thermograms of PLT 70/30 copolymer after 0, 10, 30, 60, and 90 days *in vivo* degradation: (A) first heating scan; (B) second heating scan.

It is of interest to follow the morphological changes of the samples during degradation. PLT 70/30 is initially an amorphous copolymer which only exhibits a glass transition. The T_g determined at the second heating scan shows a gradual decrease from initial 40.5° to 32.8° at 60 days. Interestingly, a small endothermic peak is observed at 73.0°C with a melting enthalpy (ΔH_m) of 6.8 J/g at 60 days, indicating crystallization of degradation by-products. A larger melting peak is detected at 104.1°C with a ΔH_m of 38.6 J/g at 90 days. In fact, PLT 70/30 has a blocky chain structure with a l_{LL} of 6.42 (Table 1). Thus low molar mass LLA-rich segments produced by degradation are able to crystallize at 37°C due to higher chain mobility as compared to long chains, as previously reported in literature. [27,49,50] Once crystallized, the PLLA-rich segments became more resistant to hydrolytic degradation. As a consequence, the LLA/TMC ratio increased at the late stage of degradation. The T_g also increased from 32.8°C at 60 days to 42.6°C at 90 days because the T_g of PLLA is much higher than that of PTMC.

3.6 Histocompatibility evaluation

The histological examination at different stages post-implantation is shown in Figure 10. After 10 days, no edema or congestion was observed around the tissue. New tissue began to wrap the sample, and it was not easy to distinguish the boundary between the sample and the

tissues. The new tissue is predominantly composed of fibroblasts and macrophage cells. But neutrophils, lymphocytes and new capillaries were also observed. At 30 days, the occluder samples were wrapped by a white fiber tissue which formed a loose and rather thick capsule. The capsule was composed of three layers: a foam cell layer near the occluder consisting of degraded copolymer debris phagocytized by macrophages, a middle fibroblast layer, and an outer fibrocellular layer. The three layers were loosely aligned around the occluder. Capillaries and some lymphocytes were observed inside the capsule structure. No edema or hyperemia was observed. At 60 days, the capsule wall became globally thinner and more compact. Thinning of the fibrocellular and fibroblast layers was detected, together with thickening of the foam cell layer and the presence of some multinucleated and plasma cells. At 90 days, the fibrous capsule wall turned thinner and denser, and could be easily detached. The boundaries between the three layers almost disappeared. Similar observations were made at 120 days. Foam cells and a few lymphocytes were found in the capsule.

Figure 10. Histological examination at different stages after occluder implantation (original magnification. X200). (A) 10 days; (B) 30 days; (C) 60 days; (D) 90 days; (E) 120 days.

The degradation of PLT copolymer occluders can be divided in two periods. In the first period, the molar mass gradually decreases without weight loss. Inflammatory response was

detected in the peripheral tissue after 10 days implantation. In the second period from 30 days, weight loss occurred until total degradation of the occluders. Small crystalline particles were obtained during degradation of the material. Meanwhile, macrophages were activated, resulting in the inflammatory reaction. A large number of macrophages englobed the crystalline particles, and thus yielding a foam cell layer. With the time passing by, the foam cells number progressively decreased, and so did the inflammatory reaction. In general, the endothelialization was completed within 3 months of implantation.

Severe inflammatory reactions are not desirable from the histocompatibility aspect. Nevertheless, moderate inflammatory reaction could be helpful to complete endothelialization of the occluder. Cardiac endothelial cells would progressively cover the occluder after implantation, and endothelialization would be completed in 1-3 months. Occluder needs to fulfil its function of blocking and supporting before endothelialization, should be degraded soon after complete endothelialization. If the occluder degrades too quickly, the radial support would quickly decline. Thus the effective support and blocking effect would be deficient. And accumulation of large amounts of degradation products in a short time could lead to occurrence of inflammation and endothelial hyperplasia. On the other hand, if the degradation time is too long, occluders could cause inflammation, and could lead to formation of complications such as thrombosis. Further studies are underway in our group to optimize the copolymer properties, the design of occluder architecture, and the matching of the occluders and the guidewires for potential clinical applications.

4 Conclusion

In this work, a series of high molar mass poly(L-lactide-co-trimethylene carbonate) (PLT) copolymers were synthesized and characterized. All copolymers exhibit only one glass transition, and the addition of TMC component leads to T_g decrease. The tensile strength of copolymers decreases with increasing the content of TMC component, while the elongation at

break increases. In vitro degradation of PLT copolymers with higher TMC content is slower than that with lower TMC content because TMC units are more resistant to hydrolytic cleavage. The various PLT copolymers present good hemocompatibility and low cytotoxicity as revealed by the hemolysis, dynamic clotting, plasma recalcification and MTT tests.

In vivo degradation was realized by implantation of 3D printed PLT 70/30 occluders in rabbits. Degradation rate was almost completed after 120 days. In particular, crystallization of PLLA degradation by-products was observed. Visual observation and H&E staining analysis confirmed the good tissue compatibility of occluders. Therefore, PLLA-TMC copolymers could be promising for potential applications as degradable occluder material.

Acknowledgment

The work is supported by the Science and Technology Development Plan of Shandong Province (2018GGX102016) and the 2018 Shandong Province Graduate Education Joint Training Base Construction Project.

References

- [1] M. Nassif, M. Abdelghani, B. J. Bouma, B. Straver, N. A. Blom, K. T. Koch, J. G. P. Tijssen, B. J. M. Mulder, R. J. De Winter, Historical developments of atrial septal defect closure devices: what we learn from the past, *Expert Review of Medical Devices* 13 (6) (2016) 555-568.
- [2] B. Y. Tang, F. Su, X. K. Sun, Q. Wu, Q. S. Xing, S. M. Li, Recent development of transcatheter closure of atrial septal defect and patent foramen ovale with occluders, *Journal of Biomedical Materials Research Part B-Applied Biomaterials* 106 (1) (2018) 433-443.
- [3] Z. Jalal, S. Hascoet, C. Gronier, F. Godart, L. Mauri, C. Dauphin, B. Lefort, M. Lachaud, D. Piot, M. L. Dinet, Y. Levy, A. Fraisse, C. Ovaert, X. Pillois, J. R. Lusson, J. Petit, A. E. Baruteau, J. B. Thambo, Long-Term Outcomes After Percutaneous Closure of Ostium Secundum Atrial Septal Defect in the Young A Nationwide Cohort Study, *Jacc-Cardiovascular Interventions* 11 (8) (2018) 795-804.

- [4] M. F. Lopez, B. Krastins, D. A. Sarracino, G. Byram, M. S. Vogelsang, A. Prakash, S. Peterman, S. Ahmad, G. Vadali, W. J. Deng, I. Inglessis, T. Wickham, K. Feeney, G. W. Dec, I. Palacios, F. S. Buonanno, E. H. Lo, M. M. Ning, Proteomic signatures of serum albumin-bound proteins from stroke patients with and without endovascular closure of PFO are significantly different and suggest a novel mechanism for cholesterol efflux, *Clinical Proteomics* 12 (2015).
- [5] C. M. Happel, K. T. Laser, M. Sigler, D. Kececioglu, E. Sandica, N. A. Haas, Single Center Experience: Implantation Failures, Early, and Late Complications After Implantation of a Partially Biodegradable ASD/PFO-Device (BioStar (R)), *Catheterization and Cardiovascular Interventions* 85 (6) (2015) 990-997.
- [6] Y. Y. Huang, J. F. Kong, S. S. Venkatraman, Biomaterials and design in occlusion devices for cardiac defects: A review, *Acta Biomaterialia* 10 (3) (2014) 1088-1101.
- [7] S. F. Rimoldi, S. R. Ott, E. Rexhaj, R. Von Arx, S. F. De Marchi, R. Brenner, U. Scherrer, B. Meier, M. Gugger, Y. Allemann, C. Seiler, Effect of Patent Foramen Ovale Closure on Obstructive Sleep Apnea, *Journal of the American College of Cardiology* 65 (20) (2015) 2257-2258.
- [8] M. J. Mullen, D. Hildick-Smith, J. V. De Giovanni, C. Duke, W. S. Hillis, W. L. Morrison, C. Jux, BioSTAR Evaluation Study (BEST): a prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts, *Circulation* 114 (18) (2006) 1962-7.
- [9] D. Duong-Hong, Y. D. Tang, W. Wu, S. S. Venkatraman, F. Boey, J. Lim, J. Yip, Fully Biodegradable Septal Defect Occluder-A Double Umbrella Design, *Catheterization and Cardiovascular Interventions* 76 (5) (2010) 711-718.
- [10] Y. F. Zhu, X. M. Huang, J. Cao, J. Q. Hu, Y. Bai, H. B. Jiang, Z. F. Li, Y. Chen, W. Wang, Y. W. Qin, X. X. Zhao, Animal Experimental Study of the Fully Biodegradable Atrial Septal Defect (ASD) Occluder, *Journal of Biomedicine and Biotechnology* (2012).
- [11] M. Abu Ghalia, Y. Dahman, Biodegradable poly(lactic acid)-based scaffolds: synthesis and biomedical applications, *Journal of Polymer Research* 24 (5) (2017).
- [12] S. Venkatraman, T. L. Poh, T. Vinalia, K. H. Mak, F. Boey, Collapse pressures of biodegradable stents, *Biomaterials* 24 (12) (2003) 2105-2111.
- [13] Y. Ramot, M. Haim-Zada, A. J. Domb, A. Nyska, Biocompatibility and safety of PLA and its copolymers, *Advanced Drug Delivery Reviews* 107 (2016) 153-162.
- [14] N. Saba, M. Jawaaid, O. Al-Othman, An Overview on Polylactic Acid, its Cellulosic Composites and Applications, *Current Organic Synthesis* 14 (2) (2017) 156-170.

- [15] A. Smola, P. Dobrzynski, M. Cristea, J. Kasperczyk, M. Sobota, K. Gebarowska, H. Janeczek, Bioresorbable terpolymers based on L-lactide, glycolide and trimethylene carbonate with shape memory behaviour, *Polymer Chemistry* 5 (7) (2014) 2442-2452.
- [16] A. K. Matta, R. U. Rao, K. N. S. Suman, V. Rambabu, Preparation and Characterization of Biodegradable PLA/PCL Polymeric Blends, *Procedia Materials Science* 6 (2014) 1266-1270.
- [17] C. Zhang, D. H. Liu, X. W. Zhang, P. Wang, Z. Zhen, J. X. Li, D. X. Yi, Y. Jin, D. Yang, Design and in vivo assessment of polyester copolymers based on trimethylene carbonate and epsilon-caprolactone, *Journal of Applied Polymer Science* 132 (16) (2015).
- [18] A. P. Pego, M. J. A. Van Luyn, L. A. Brouwer, P. B. van Wachem, A. A. Poot, D. W. Grijpma, J. Feijen, In vivo behavior of poly (1, 3-trimethylene carbonate) and copolymers of 1, 3-trimethylene carbonate with D, L-lactide or ϵ -caprolactone: Degradation and tissue response, 67 (2003) 1044-1054.
- [19] K. Noorsal, M. D. Mantle, L. F. Gladden, R. E. Cameron, Degradation and drug-release studies of a poly(glycolide-co-trimethylene carbonate) copolymer (Maxon), *Journal of Applied Polymer Science* 95 (3) (2005) 475-486.
- [20] B. Y. Yan, Z. P. Zhang, X. P. Wang, Y. F. Ni, Y. S. Liu, T. Liu, W. P. Wang, H. Xing, Y. Sun, J. Wang, X. F. Li, PLGA-PTMC-Cultured Bone Mesenchymal Stem Cell Scaffold Enhances Cartilage Regeneration in Tissue-Engineered Tracheal Transplantation, *Artificial Organs* 41 (5) (2017) 461-469.
- [21] H. Zhao, Y. L. Wang, J. R. Peng, L. Zhang, Y. Qu, B. Y. Chu, M. L. Dong, L. W. Tan, Z. Y. Qian, Biodegradable Self-Assembled Micelles Based on MPEG-PTMC Copolymers: An Ideal Drug Delivery System for Vincristine, *Journal of Biomedical Nanotechnology* 13 (4) (2017) 427-436.
- [22] S. Mukherjee, C. Gualandi, M. L. Focarete, R. Ravichandran, J. R. Venugopal, M. Raghunath, S. Ramakrishna, Elastomeric electrospun scaffolds of poly(l-lactide-co-trimethylene carbonate) for myocardial tissue engineering, *Journal of Materials Science-Materials in Medicine* 22 (7) (2011) 1689-1699.
- [23] C. Marchesi, M. Pluderi, F. Colleoni, M. Belicchi, M. Meregalli, A. Farini, D. Parolini, L. Draghi, M. E. Fruguglietti, M. Gavina, L. Porretti, A. Cattaneo, M. Battistelli, A. Prella, M. Moggio, S. Borsa, L. Bello, D. Spagnoli, S. M. Gaini, M. C. Tanzi, N. Bresolin, N. Grimoldi, Y. Torrente, Skin-derived stem cells transplanted into resorbable guides provide functional nerve regeneration after sciatic nerve resection, *Glia* 55 (4) (2007) 425-38.
- [24] N. Andronova, A. C. Albertsson, Resilient bioresorbable copolymers based on

- trimethylene carbonate, L-lactide, and 1,5-dioxepan-2-one, *Biomacromolecules* 7 (5) (2006) 1489-95.
- [25] K. Jelonek, J. Kasperczyk, S. M. Li, P. Dobrzynski, B. Jarzabek, Controlled poly(L-lactide-co-trimethylene carbonate) delivery system of cyclosporine A and rapamycin - the effect of copolymer chain microstructure on drug release rate, *International Journal of Pharmaceutics* 414 (1-2) (2011) 203-209.
- [26] K. Jelonek, B. Kaczmarczyk, J. Jaworska, M. Pastusiak, M. Sobota, P. Dobrzynski, J. Kasperczyk, The influence of drug-polymer interactions on release of antirestenotic agent from bioresorbable scaffolds, *Materials Letters* 223 (2018) 82-85.
- [27] J. J. Hua, K. Gebarowska, P. Dobrzynski, J. Kasperczyk, J. Wei, S. M. Li, Influence of chain microstructure on the hydrolytic degradation of copolymers from 1,3-trimethylene carbonate and L-lactide, *Journal of Polymer Science Part A-Polymer Chemistry* 47 (15) (2009) 3869-3879.
- [28] J. Yang, F. Liu, L. Yang, S. M. Li, Hydrolytic and enzymatic degradation of poly(trimethylene carbonate-co-D,L-lactide) random copolymers with shape memory behavior, *European Polymer Journal* 46 (4) (2010) 783-791.
- [29] Q. K. Guo, Z. Q. Lu, Y. Zhang, S. M. Li, J. Yang, In vivo study on the histocompatibility and degradation behavior of biodegradable poly(trimethylene carbonate-co-D,L-lactide), *Acta Biochimica et Biophysica Sinica* 43 (6) (2011) 433-440.
- [30] L. Liao, J. T. Dong, L. Shi, Z. Y. Fan, S. M. Li, Z. Q. Lu, In vitro degradation behavior of L-lactide/trimethylene carbonate/glycolide terpolymers and a composite with poly(L-lactide-co-glycolide) fibers, *Polymer Degradation and Stability* 111 (2015) 203-210.
- [31] H. L. Li, J. P. Chang, Y. Y. Qin, Y. Wu, M. L. Yuan, Y. J. Zhang, Poly(lactide-co-trimethylene carbonate) and Polylactide/Polytrimethylene Carbonate Blown Films, *International Journal of Molecular Sciences* 15 (2) (2014) 2608-2621.
- [32] E. A. Bender, M. D. Adorne, L. M. Colome, D. S. P. Abdalla, S. S. Guterres, A. R. Pohlmann, Hemocompatibility of poly(epsilon-caprolactone) lipid-core nanocapsules stabilized with polysorbate 80-lecithin and uncoated or coated with chitosan, *International Journal of Pharmaceutics* 426 (1-2) (2012) 271-279.
- [33] S. Manju, K. Sreenivasan, Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: Blood compatibility evaluation and targeted drug delivery onto cancer cells, *Journal of Colloid and Interface Science* 368 (2012) 144-151.
- [34] F. Su, X. Shen, Y. F. Hu, V. Darcos, S. M. Li, Biocompatibility of thermo-responsive

- PNIPAAm-PLLA-PNIPAAm triblock copolymer as potential drug carrier, *Polymers for Advanced Technologies* 26 (12) (2015) 1567-1574.
- [35] E. L. Zhang, H. Y. Chen, F. Shen, Biocorrosion properties and blood and cell compatibility of pure iron as a biodegradable biomaterial, *Journal of Materials Science-Materials in Medicine* 21 (7) (2010) 2151-2163.
- [36] Y. Nie, Y. Duan, Z. Zhang, Evaluation of blood compatibility of surface modification treated poly (D, L-lactic and glycolic acid) with mPEG block copolymer, *Journal of Biomedical Engineering* 24 (2) (2007) 336-9.
- [37] Z. Q. He, L. Z. Xiong, In-vitro Response of Fibroblasts to Poly-L-lactide Composite Materials Containing Bovine Bone, *Polymers & Polymer Composites* 20 (6) (2012) 531-535.
- [38] U. Krumdorf, S. Ostermayer, K. Billinger, T. Trepels, E. Zadan, K. Horvath, H. Sievert, Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients, *Journal of the American College of Cardiology* 43 (2) (2004) 302-9.
- [39] L. Liao, J. T. Dong, G. X. Wang, Z. Y. Fan, S. M. Li, Z. Q. Lu, Microstructure-property relationship of L-lactide/trimethylene carbonate/glycolide terpolymers as cardiovascular stent material, *European Polymer Journal* 66 (2015) 429-436.
- [40] X. Zhang, M. A. Geven, D. W. Grijpma, J. E. Gautrot, T. Peijs, "Polymer-polymer composites for the design of strong and tough degradable biomaterials", *Materials Today Communications* 8 (2016) 53-63.
- [41] J. T. Dong, L. Liao, L. Shi, Z. S. Tan, Z. Y. Fan, S. M. Li, Z. Q. Lu, A bioresorbable cardiovascular stent prepared from L-lactide, trimethylene carbonate and glycolide terpolymers, *Polymer Engineering and Science* 54 (6) (2014) 1418-1426.
- [42] J. T. Dong, L. Liao, Y. Ma, L. Shi, G. X. Wang, Z. Y. Fan, S. M. Li, Z. Q. Lu, Enzyme-catalyzed degradation behavior of L-lactide/trimethylene carbonate/glycolide terpolymers and their composites with poly(L-lactide-co-glycolide) fibers, *Polymer Degradation and Stability* 103 (2014) 26-34.
- [43] Z. Zhang, R. Kuijjer, S. K. Bulstra, D. W. Grijpma, J. Feijen, The in vivo and in vitro degradation behavior of poly(trimethylene carbonate), *Biomaterials* 27 (9) (2006) 1741-1748.
- [44] Y. R. Han, Z. Y. Fan, Z. Q. Lu, Y. Zhang, S. M. Li, In vitro Degradation of Poly[(L-lactide)-co-(trimethylene carbonate)] Copolymers and a Composite with Poly[(L-lactide)-co-glycolide] Fibers as Cardiovascular Stent Material, *Macromolecular*

Materials and Engineering 297 (2) (2012) 128-135.

- [45]J. Li, W. Zheng, Y. F. Zheng, X. Lou, Cell responses and hemocompatibility of g-HA/PLA composites, *Science China-Life Sciences* 54 (4) (2011) 366-371.
- [46]B. C. Dash, G. Rethore, M. Monaghan, K. Fitzgerald, W. Gallagher, A. Pandit, The influence of size and charge of chitosan/polyglutamic acid hollow spheres on cellular internalization, viability and blood compatibility, *Biomaterials* 31 (32) (2010) 8188-8197.
- [47]Q. S. Zhu, L. B. Chen, P. Y. Zhu, J. F. Luan, C. Mao, X. H. Huang, J. Shen, Preparation of PNIPAM-g-P (NIPAM-co-St) microspheres and their blood compatibility, *Colloids and Surfaces B-Biointerfaces* 104 (2013) 61-65.
- [48]Y. L. Luo, C. H. Zhang, F. Xu, Y. S. Chen, Novel THTPBA/PEG-derived highly branched polyurethane scaffolds with improved mechanical property and biocompatibility, *Polymers for Advanced Technologies* 23 (3) (2012) 551-557.
- [49]M. Therin, P. Christel, S. Li, H. Garreau, M. Vert, In vivo degradation of massive poly (α -hydroxy acids): validation of in vitro findings, *Biomaterials* 13 (1992) 594.
- [50]J. Fernandez, A. Larranaga, A. Etxeberria, J. R. Sarasua, Effects of chain microstructures and derived crystallization capability on hydrolytic degradation of poly(L-lactide/epsilon-caprolactone) copolymers, *Polymer Degradation and Stability* 98 (2) (2013) 481-489.

Declaration of interest

On behalf of all authors, I declare that there are **no Conflicts of Interest** in this work.

Suming LI

July 2nd, 2019